13 High Growth Pharma Stocks that are Profitable

Published on February 23, 2023 at 10:50 am by Ramish Cheema in Lists, News

In this piece, we will take a look at 13 high growth pharma stocks that are profitable. For more stocks, head on over to 5 High Growth Pharma Stocks that are Profitable.

One industry that has rapidly evolved with time and impacted millions, if not billions, of lives is the pharmaceutical sector. Within a hundred years, humanity has managed to cure and prevent diseases that were the cause of death in the pre technological era. One disease that is thought to be mild today but caused widespread loss of life in the early 20th century was syphilis, and data from the Centers for Disease Control (CDC) shows that pneumonia, tuberculosis, and diarrhea consistently ranked among the top four causes of death in the United States between 1900 and 1923 – with millions of people seeing a premature end to their lives.

However, by 1998, only pneumonia ranked in the top ten causes of death in the U.S., and the latest CDC data for 2021 shows that the picture has completely changed as pneumonia is out of the list. This complete shift in the list of causes of death is due to rapid advances made by the pharmaceutical industry, which have reduced deadly diseases of the past to manageable or avoidable illnesses today. This is evidenced by the fact that a Federal Trade Commission (FTC) study that attempted to look into the effects of antibiotics on American health found that between 1946 and 1955, tuberculosis deaths ended up dropping by a stunning 75%.

These days, the pharmaceutical industry has moved forward from simple diseases to leveraging advanced technologies such as gene editing to combat complex illnesses such as cancer. A research report from McKinsey points out the growing role of mRNA technologies in the industry, outlining that these combined with gene and cell therapies have grown from 11% of the total drug development efforts to 21% – in a first for the industry. It adds that this shift in modalities combined with innovational pressure and a loss of power from individual players will be the driving factors for the sector in the future.

Today, we’ll take a look at pharmaceutical companies that are both growing and generating profits. Out of these, the top players are SIGA Technologies, Inc. (NASDAQ:SIGA), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), and Precigen, Inc. (NASDAQ:PGEN).

Photo by Spencer Davis on Unsplash

Our Methodology

We used a stock tracker to first list down healthcare companies that have a profit margin higher than 25% and an annual quarterly sales growth higher than 20%. These curated companies were then analyzed to determine if they are pharmaceutical firms, such as those that make vaccines, drugs, or therapies, or others such as medical device manufacturers. Then, the constraints were relaxed to firms with a 15% or higher sales growth and the selection process was repeated. Out of all these, the top fifteen were selected and ranked through their sales growth, which was manually calculated to verify the screener’s figures with the latest earnings reports of the firms.

High Growth Pharma Stocks that are Profitable

13. United Therapeutics Corporation (NASDAQ:UTHR)

Q/Q Sales Growth: 16%

Number of Hedge Fund Holders in Q3 2022: 47

United Therapeutics Corporation (NASDAQ:UTHR) is an American biotechnology firm headquartered in Silver Spring, Maryland. The firm manufactures drugs for a variety of complications related to pulmonary hypertension, such as lung and exercise capacity.

United Therapeutics Corporation (NASDAQ:UTHR)’s September quarter of 2022 saw the firm rake in $516 million in revenue, which marked a 16% annual growth. During the same quarter, 47 of the 920 hedge funds polled by Insider Monkey had also held a stake in the company.

United Therapeutics Corporation (NASDAQ:UTHR)’s largest investor is Kurt Von Emster’s VenBio Select Advisor which owns 2.8 million shares that are worth $796 million.

Along with Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), SIGA Technologies, Inc. (NASDAQ:SIGA), and Precigen, Inc. (NASDAQ:PGEN), United Therapeutics Corporation (NASDAQ:UTHR) is a high growth profitable pharma firm.

12. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Q/Q Sales Growth: 16.4%

Number of Hedge Fund Holders in Q3 2022: 20

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is a biopharmaceutical company headquartered in New York, New York. The company sells a treatment for biliary cholangitis – a liver disease that damages the bile duct. It is also developing other drugs.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) scored a win in January 2023 when the FDA accepted its new drug application for a liver fibrosis treatment. The firm’s revenue grew by 16.4% during its fiscal quarter that ended in September 2022, and Insider Monkey’s 920 hedge fund survey for the same time period revealed that 20 had bought its shares.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)’s largest investor is Srini Akkaraju and Michael Dybbs’s Samsara BioCapital which owns 640,688 shares that are worth $7.9 million.

11. Novo Nordisk A/S (NYSE:NVO)

Q/Q Sales Growth: 27%

Number of Hedge Fund Holders in Q3 2022: 40

Novo Nordisk A/S (NYSE:NVO) is one of the oldest pharmaceutical companies in the world since it was set up in 1923. The firm makes and sells drugs for diabetes, obesity, growth disorders, and other health issues.

Novo Nordisk A/S (NYSE:NVO) reported DKK 48 billion in revenues for its fourth quarter of 2022, which marked a 27% growth over the year ago quarter’s DKK 38.3 billion. Insider Monkey’s Q3 2022 survey of 920 hedge funds revealed that 40 had held a stake in the firm.

Out of these, Jim Simons’ Renaissance Technologies is Novo Nordisk A/S (NYSE:NVO)’s largest investor. It owns 12.6 million shares that are worth $1.7 billion.

10. Avid Bioservices, Inc. (NASDAQ:CDMO)

Q/Q Sales Growth: 32.9%

Number of Hedge Fund Holders in Q3 2022: 15

Avid Bioservices, Inc. (NASDAQ:CDMO) is a contract manufacturing pharmaceutical company that produces drugs and other related products for different firms. These include making antibodies and proteins, alongside other services such as regulatory support. The firm is based in Tustin, California.

Avid Bioservices, Inc. (NASDAQ:CDMO)’s second quarter of its fiscal year 2023, which ended in October last year, saw the firm earn $34.7 million in revenue which marked a 32.9% annual growth. At the same time, the firm also increased its revenue guidance for fiscal 2023 to $150 million from $145 million. 15 of the 920 hedge funds polled by Insider Monkey for last year’s third quarter had invested in the firm.

9. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Q/Q Sales Growth: 45%

Number of Hedge Fund Holders in Q3 2022: 27

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a pharmaceutical firm that focuses on making products for people with neurological problems such as sleep disorders. The firm is headquartered in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) had a bumper third quarter last year when it reported a 45% annual revenue growth that pushed its revenue to $117 million. Insider Monkey scoured through 920 hedge fund holdings for the same time period and found out that 27 had bought its shares.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)’s largest investor is Albert Cha and Frank Kung’s Vivo Capital which owns 2.6 million shares that are worth $143 million.

8. Dynavax Technologies Corporation (NASDAQ:DVAX)

Q/Q Sales Growth: 53%

Number of Hedge Fund Holders in Q3 2022: 22

Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical firm that is headquartered in Emeryville, California. The firm makes and sells hepatitis vaccines.

Dynavax Technologies Corporation (NASDAQ:DVAX)’s fiscal third quarter, which ended in September 2022, saw the firm post $167 million in revenues to mark a 53% annual growth. 22 of the 920 hedge funds part of Insider Monkey’s survey for the same time period had invested in the firm.

Dynavax Technologies Corporation (NASDAQ:DVAX)’s largest investor is Ken Fisher’s Fisher Asset Management which owns 4 million shares that are worth $43 million.

7. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Q/Q Sales Growth: 61%

Number of Hedge Fund Holders in Q3 2022: 18

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) develops and sells treatments for diseases such as muscular atrophy, pressure palsies, and a rare condition in children that harms the signals sent from the nerves to the muscles. It is headquartered in Coral Gables, Florida.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) had a bumper fiscal year in 2022, as the firm posted a whopping 52% revenue growth by bringing in $214 million in revenues. For the fourth quarter, the growth was even stronger, as it stood at 61%. During Q3 2022, 18 of the 920 hedge funds polled by Insider Monkey had invested in the firm.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)’s largest investor is James E. Flynn’s Deerfield Management which owns 5.8 million shares that are worth $109 million.

6. Genmab A/S (NASDAQ:GMAB)

Q/Q Sales Growth: 73.9%

Number of Hedge Fund Holders in Q3 2022: 12

Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company that develops treatments for cancer, eye diseases, multiple sclerosis, solid tumors, atrophy, celiac disease, and other health problems. The firm was set up in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S (NASDAQ:GMAB)’s on a high rolling path. Its third quarter of 2022 revenue saw it bring in DKK 4 billion in sales, marking a 73.9% increase. This growth came after the firm had posted a stunning 68% growth in the previous quarter. Insider Monkey’s Q3 2022 survey of 920 hedge funds revealed that 12 had bought the firm’s shares.

Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital is Genmab A/S (NASDAQ:GMAB)’s largest investor. It owns a $74 million stake that comes via 1.7 million shares.

SIGA Technologies, Inc. (NASDAQ:SIGA), Genmab A/S (NASDAQ:GMAB), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), and Precigen, Inc. (NASDAQ:PGEN) are some of the highest growth and profitable pharmaceutical companies.

Click to continue reading and see 5 High Growth Pharma Stocks that are Profitable.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up